Pick the best stocks and maximize your portfolio:
- Discover top-rated stocks from highly ranked analysts with Analyst Top Stocks!
- Easily identify outperforming stocks and invest smarter with Top Smart Score Stocks
Sangamo Biosciences ( (SGMO) ) has shared an announcement.
Sangamo Therapeutics faced legal challenges over a stock increase amendment, but the Delaware Court of Chancery validated the voting process, clearing uncertainties. Meanwhile, in collaboration with Pfizer, Sangamo presented promising results from the Phase 3 AFFINE trial for a gene therapy targeting hemophilia A, showing significant reductions in bleeding rates. These developments are pivotal for investors tracking Sangamo’s strategic moves and the broader gene therapy market.
See more insights into SGMO stock on TipRanks’ Stock Analysis page.
